The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases

Alex J. Liu, Heidi E. Kosiorek, Benjamin E. Ueberroth, Ellen Jaeger, Elisa Ledet, Ayse T. Kendi, Katherine Tzou, Fernando Quevedo, Richard Choo, Cassandra N. Moore, Thai H. Ho, Parminder Singh, Sameer R. Keole, William W. Wong, Oliver Sartor, Alan H. Bryce

Research output: Contribution to journalArticlepeer-review


Background: Radium (Ra)-223 is an established treatment option for patients with metastatic castrate-resistant prostate cancer (mCRPC) who have symptomatic bone metastases without soft tissue disease. Studies have indicated genetic aberrations that regulate DNA damage response (DDR) in prostate cancer can increase susceptibility to treatments such as poly ADP-ribose polymerase inhibitors and platinum-based therapies. This study aims to evaluate mCRPC response to Ra-223 stratified by tumor genomics. Methods: This is a retrospective study of mCRPC patients who received Ra-223 and genetic testing within the Mayo Clinic database (Arizona, Florida, and Minnesota) and Tulane Cancer Center. Patient demographics, genetic aberrations, treatment responses in terms of alkaline phosphatase (ALP) and prostate-specific antigen (PSA), and survival were assessed. Primary end points were ALP and PSA response. Secondary end points were progression-free survival (PFS) and overall survival (OS) from time of first radium treatment. Results: One hundred and twenty-seven mCRPC patients treated with Ra-223 had germline and/or somatic genetic sequencing. The median age at time of diagnosis and Ra-223 treatment was 61.0 and 68.6 years, respectively. Seventy-nine (62.2%) had Gleason score ≥ 8 at time of diagnosis. 50.4% received prior docetaxel, and 12.6% received prior cabazitaxel. Notable alterations include TP53 (51.7%), BRCA 1/2 (15.0%), PTEN (13.4%), ATM (11.7%), TMPRSS2-ERG (8.2%), RB deletion (3.4%), and CDK12 (1.9%). There was no significant difference in ALP or PSA response among the different genetic aberrations. Patients with a TMPRSS2-ERG mutation exhibited a trend toward lower OS 15.4 months (95% confidence interval [CI] 10.0−NR) versus 26.8 months (95% CI 20.9−35.1). Patients with an RB deletion had a lower PFS 6.0 months (95% CI 1.28−NR) versus 9.0 months (95% CI 7.3−11.1) and a lower OS 13.9 months (95% CI 5.2−NR) versus 26.5 months (95% CI 19.8−33.8). Conclusions: Among mCRPC patients treated with Ra-223 at Mayo Clinic and Tulane Cancer Center, we did not find any clear negative predictors of biochemical response or survival to treatment. TMPRSS2-ERG and RB mutations were associated with a worse OS. Prospective studies and larger sample sizes are needed to determine the impact of genetic aberrations in response to Ra-223.

Original languageEnglish (US)
Pages (from-to)1202-1209
Number of pages8
Issue number12
StatePublished - Sep 1 2022


  • Ra-223
  • bone metastases
  • germline
  • metastatic castration-resistant prostate cancer
  • mutation
  • somatic

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases'. Together they form a unique fingerprint.

Cite this